{"nctId":"NCT00448747","briefTitle":"Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test.","startDateStruct":{"date":"2007-06"},"conditions":["Diagnosis of Adult Growth Hormone Deficiency (AGDH)"],"count":101,"armGroups":[{"label":"AEZS-130 ( formerly ARD-07)","type":"EXPERIMENTAL","interventionNames":["Drug: AEZS-130 (formerly ARD-07)"]},{"label":"L-ARG+GHRH","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: L-ARG+GHRH"]}],"interventions":[{"name":"AEZS-130 (formerly ARD-07)","otherNames":["Test 1","Macimorelin"]},{"name":"L-ARG+GHRH","otherNames":["Test Control"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion for Matched Control Subjects:\n\n* Undergone normal growth and development\n* Normal serum prolactin (PRL) concentrations\n* Females should have a history of regular, age-appropriate menses\n* Males should have normal serum testosterone concentrations\n* Matched GHD subject already enrolled in study; matched in terms of sex, age, BMI and Estrogen status (women only)\n\nExclusion Criteria for Matched Control Subjects:\n\n* Inability or unwillingness to comply with study medication\n* Pregnancy or lactation\n* Clinically relevant ECG abnormalities (including QT/QTc interval \\> 450 ms) at any time prior to dosing at Visit 2\n* Treatment with any drugs that might prolong QT/QTc\n\nInclusion criteria dor Adult GHD Subjects:\n\n* Confirmed GH deficiency with a low IGF-1\n* 3 months of stable treatment for those requiring hormone replacement therapy for hormones deficiencies other than GHD\n* subjects with hypogonadism must be treated with sex steroid therapy, excluding women over 50 yr of age\n* women on estrogen therapy, for whatever reason, must be on stable treatment for ar least 3 months prior to study\n\nExclusion criteria for Adult GHD Subjects:\n\n* Untreated hypothyroidism\n* Known hypersensitivity to any excipient in study medication\n* Inability or unwillingness to comply with study procedures\n* Intracranial lesions stable for less than 12 months\n* GH therapy within one month of study entry\n* Clinically significant cardiovascular, or cerebrovascular disease\n* Current active malignancy other than non-melanoma skin cancer\n* Renal or hepatic dysfunction (\\> 3 x ULN liver function enzymes (LFEs) - aspartate amino transferase (ASAT); alanine amino transferase (ALAT); gamma-glutamyltransferase (GGT) or creatinine \\> 2x ULN)\n* Pregnancy or lactation\n* Active Cushing's disease\n* Clinically relevant ECG abnormalities (including QT/heart rate corrected QT interval (QTc) interval \\> 450 ms) at any time prior to dosing at Visit 2\n* Treatment with any drugs that might prolong QT/QTc","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Receiver Operating Characteristic (ROC) Analysis on Peak GH (Growth Hormon) Concentrations","description":"The primary endpoint for each individual is the peak GH concentration following AEZS-130 (macimorelin) administration.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.36","spread":"5.69"},{"groupId":"OG001","value":"17.71","spread":"19.11"}]}]}]},{"type":"SECONDARY","title":"Peak Insulin-Like Growth Factor (IGF)-1 Concentration Following Treatment","description":"Descriptive summaries for IGF-1 and correlation with GH concentrations based on macimorelin treatment. Mean IGF-1 values taken pre- and post- macimorelin administration.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.1","spread":"37.29"},{"groupId":"OG001","value":"128.1","spread":"52.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.0","spread":"34.57"},{"groupId":"OG001","value":"125.9","spread":"54.26"}]}]}]},{"type":"SECONDARY","title":"Classification and Regression Tree (CART) Analysis of Peak Growth Hormone (GH) Following Macimorelin Administration","description":"The CART Analysis for macimorelin estimated: a) a macimorelin cut-point that minimized the misclassification of AGHD patients and healthy control subjects; b) an optimal decision tree for macimorelin that incorporated age, sex and BMI.\n\nSensitivity (correct identification of AGHD cases) and specificity (correct identification of control subjects) for macimorelin was summarized for age, gender, BMI and estrogen status subgroups containing n \\> 10.\n\nAt least 8 of the 10 newly enrolled AGHD patients should have been correctly classified for a protocol pre-specified threshold of Peak GH concentration which was 8.5 (ng/ml).\n\nSoftware CART Version 6.0 was used.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","spread":null},{"groupId":"OG001","value":"11.2","spread":null},{"groupId":"OG002","value":"10.2","spread":null},{"groupId":"OG003","value":"9.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.0","spread":null},{"groupId":"OG001","value":"92.0","spread":null},{"groupId":"OG002","value":"90.0","spread":null},{"groupId":"OG003","value":"86.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null},{"groupId":"OG001","value":"85.4","spread":null},{"groupId":"OG002","value":"89.6","spread":null},{"groupId":"OG003","value":"95.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Drug Related Adverse Events (AEs)","description":"Total number of participants with drug related AEs, following macimorelin administration of L-Arginine (ARG) - Growth Hormone Releasing Hormone (GHRH) administration.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":52},"commonTop":["Dysgeusia","Flushing","Diarrhoea","Nausea","Feeling hot"]}}}